Top of this page
Skip navigation, go straight to the content

Investors Overview

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

After a disruptive 2020, we are all looking forward to a promising 2021…

So let’s disconnect from all screens & enjoy the simple things such as a nice chat with your beloved ones around a cup of coffee or tea (in the morning) or a glass of your favorite drink (in the evening).

Stay well and safe – lots of joy and good health!

Take care & let’s reconnect in 2021!


Antje, Isabelle & Nathalie

The UCB IR Team

IR events

DateEvent details
11 January
39th Annual J.P. Morgan Virtual Healthcare ConferenceUCB will participate from 11-14 January 2021
25 February
2020 full year resultsDetails closer to the date

2019 integrated report

image description

2020 HY report

image description

Outlook 2020 confirmed

Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges

2020 revenue

€ 5.05 - € 5.15 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] 

26% - 27%

reflecting the high R&D investment level, including the investment for the Ra Pharma pipeline

Core earnings per share

€ 4.40 - € 4.80

based on an average of 187 million shares outstanding


Contact UCB IR team or a specific team member:




UCB IR app available on Apple Store

UCB IR app available on Google Play